# Vaccine Contract Manufacturing Market

> Vaccine Contract Manufacturing Market Size, Growth Research Report By Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based), By Workflow (Downstream and Upstream), By Application (Human Use and Veterinary), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Competitor Industry Analysis and Trends Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.5%
- **2024:** $ 3.7 Billion
- **2025:** $ 4.13 Billion
- **2035:** $ 12.25 Billion
- **Key Players:** Lonza (CH), Boehringer Ingelheim(DE), Samsung Biologics (KR), Catalent (US), WuXi AppTec (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Fujifilm Diosynth Biotechnologies (JP), Vetter Pharma (DE)

**Report ID:** MRFR/HC/20412-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/vaccine-contract-manufacturing-market-22012

---

## Market Summary

Vaccine Contract Manufacturing Market Size was valued at USD 3.3 Billion in 2023. The Vaccine Contract Manufacturing market industry is projected to grow from USD 3.7 Billion in 2024 to USD 7.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.50% during the forecast period (2024 - 2032). The increased prevalence of infectious diseases, outbreaks, and pandemics worldwide is one of the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Vaccine Contract Manufacturing Market Trends**

Market CAGR for vaccine contract manufacturing is being driven by the rising vaccination rates worldwide. In the ever-evolving landscape of governmental and healthcare endeavors aimed at bolstering immunization coverage against the backdrop of infectious maladies, a pressing imperative emerges—a dire necessity for the expansion of vaccine production capacity. Within this exigent milieu, contract manufacturers emerge as veritable linchpins, wielding their prowess in the domain of vaccine production to furnish a panacea of flexible and scalable manufacturing solutions.

Endowed with specialized facilities and unwavering fidelity to regulatory strictures, these entities furnish pharmaceutical behemoths with the instrumental means to orchestrate a seamless augmentation of vaccine production capabilities. The harrowing specter of the COVID-19 pandemic has served to magnify the imperative of fortifying vaccine manufacturing prowess, propelling a surge in investments geared towards the fecundation of vaccine development and production endeavors. As the apogee of vaccination rates is charted across the global expanse, the clamor for the services rendered by vaccine contract manufacturers is poised to ascend to vertiginous heights, heralding an epoch of unprecedented market growth.

Enmeshed within the tapestry of the Vaccine Contract Manufacturing Market are the sinews of global health exigencies, wherein the specter of infectious disease outbreaks and the omnipresent shadow of pandemics serve as vanguards propelling the market's ascension. The burgeoning ubiquity of infectious pathogens, intertwined with the looming specter of bioterrorism, accentuates the exigency of vaccines as sentinels of public health. In this crucible of exigency, contract manufacturers emerge as valiant custodians, orchestrating a symphony of vaccine manufacturing prowess to assuage the tremors of global health crises.

The warp and weft of their operational ethos unfurl with alacrity in response to the tempestuous whims of outbreaks, such as the epoch-defining cataclysm of COVID-19. Their adeptness in marshaling resources to effectuate rapid escalations in production underpins the edifice of timely global vaccine accessibility. Moreover, the corridors of governmental and international coffers resound with the clarion call of investments channeled towards the augmentation of vaccine development and manufacturing, in a concerted bid to fortify the ramparts of pandemic preparedness and response.

As the ebb and flow of global health vicissitudes persist in their inexorable dance, the echo of demand reverberates through the annals of vaccine contract manufacturing services, auguring a vista characterized by robust market growth in the epochs yet to unfurl.

Technology advancements in vaccine manufacturing are driving the growth of the Vaccine Contract Manufacturing Market. Innovations such as cell culture-based production, recombinant DNA technology, and mRNA vaccine platforms have revolutionized vaccine manufacturing processes, enabling faster and more efficient production. Contract manufacturers invest in these advanced technologies to enhance their manufacturing capabilities and meet the increasing demand for vaccines. Additionally, these technologies allow for the development of novel vaccine candidates targeting a wide range of infectious diseases, including emerging pathogens and bioterrorism threats.

Furthermore, technological advancements enable contract manufacturers to improve vaccine quality, reduce production costs, and enhance scalability, making them attractive partners for pharmaceutical companies and governments seeking to expand vaccine production capacity. As technology continues to evolve, so does the vaccine contract manufacturing market revenue. For instance, Moderna signed a deal with the Canadian government to establish a messenger RNA vaccine manufacturing facility in an undisclosed location within Canada. This collaboration aims to provide Canadians with locally produced mRNA vaccines targeting respiratory viruses like SARS-CoV-2, influenza, and respiratory syncytial virus.

## **Vaccine Contract Manufacturing Market Segment Insights**

### **Vaccine Contract Manufacturing Vaccine Type Insights**

The Vaccine Contract Manufacturing Market segmentation, based on Vaccine Type, includes Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. In 2023, the Attenuated segment dominated the market, accounting for 35% of market revenue due to their effectiveness in generating robust and long-lasting immune responses against targeted pathogens. These vaccines are produced by weakening the disease-causing microorganism, allowing for safe administration while still eliciting a strong immune response. Additionally, attenuated vaccines often provide broader protection against various strains of pathogens, making them widely used in vaccination programs globally.

Contract manufacturers specialize in producing attenuated vaccines, catering to the growing demand for effective and cost-efficient immunization solutions.

Inactivated vaccines are experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. These vaccines are produced by killing the disease-causing microorganism, making them safe for administration while still eliciting an immune response. Inactivated vaccines offer advantages such as improved stability and safety profiles, making them suitable for widespread use, especially in pediatric and elderly populations. Additionally, the increasing demand for [influenza vaccines](../../../reports/influenza-vaccination-market-1621) and other inactivated vaccines to prevent infectious diseases is driving growth in this segment of vaccine manufacturing.

**Figure 1: Vaccine Contract Manufacturing Market, by Vaccine Type, 2023 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Vaccine Contract Manufacturing Workflow Insights**

The Vaccine Contract Manufacturing Market segmentation, based on Workflow, includes Downstream and Upstream. In 2023, the Downstream category generated the most income due to its critical role in vaccine production processes. This phase involves purification, concentration, and formulation of the vaccine candidate after upstream processing, ensuring the final product meets regulatory standards for safety, efficacy, and purity. Contract manufacturers specializing in downstream workflow offer expertise in purification techniques, such as [chromatography](../../../reports/chromatography-systems-market-2324) and filtration, enabling the efficient production of high-quality vaccines. Additionally, downstream workflow optimization enhances manufacturing efficiency and reduces production costs, further driving its market dominance.

Upstream workflow is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. This phase involves cell culture, fermentation, and initial processing steps critical for vaccine production. With the increasing demand for novel vaccine candidates and the emergence of advanced bioprocessing technologies, there is a growing need for contract manufacturers specializing in upstream workflow. These manufacturers offer expertise in cell line development, bioreactor operation, and process optimization, enabling efficient and scalable production of vaccine candidates, thus driving growth in this segment.

### **Vaccine Contract Manufacturing Application Insights**

The Vaccine Contract Manufacturing Market segmentation, based on Application, includes Human Use and Veterinary. In 2023, the Human Use category generated the most income due to the predominant focus on vaccines for preventing diseases in humans. Contract manufacturers specializing in human use applications are well-equipped to meet the stringent regulatory requirements and quality standards governing vaccine production for human use. Additionally, the high demand for vaccines to address public health concerns and prevent infectious diseases further drives the dominance of human use applications in vaccine contract manufacturing.

Veterinary application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. The growing awareness of animal health and welfare, coupled with increasing demand for livestock vaccines to prevent infectious diseases in animals, is driving growth in this segment. Additionally, advancements in biotechnology and genetic engineering are enabling the development of novel vaccines for veterinary use, further fueling the demand for contract manufacturing services in the veterinary vaccine market.

**Vaccine Contract Manufacturing Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America has secured the largest market share in the Vaccine Contract Manufacturing Market due to several factors. These include a well-established pharmaceutical and biotechnology industry, advanced healthcare infrastructure, and strong regulatory frameworks supporting vaccine manufacturing. Additionally, the region is home to several leading vaccine manufacturers and contract manufacturing organizations, driving innovation and growth. Moreover, strategic partnerships between government agencies, academic institutions, and industry players further enhance North America's dominance in vaccine contract manufacturing.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: VACCINE CONTRACT MANUFACTURING MARKET SHARE BY REGION 2023 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe Vaccine Contract Manufacturing market accounts for the second-largest market share due to investments in research and development. Europe has secured the second-largest market share in the Vaccine Contract Manufacturing Market due to several factors. These include a robust pharmaceutical and biotechnology sector, significant investments in research and development, and a skilled workforce. Additionally, Europe benefits from a strong regulatory environment and access to advanced manufacturing technologies, enabling contract manufacturers to meet stringent quality and safety standards. Moreover, the region's strategic location and extensive network of healthcare institutions contribute to its prominence in vaccine contract manufacturing.

Further, the German Vaccine Contract Manufacturing market held the largest market share, and the UK Vaccine Contract Manufacturing market was the fastest growing market in the European region

The Asia-Pacific Vaccine Contract Manufacturing Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. These include the increasing demand for vaccines in densely populated countries, rising investments in healthcare infrastructure, and the presence of a large skilled workforce. Additionally, favorable government initiatives, such as incentives for biopharmaceutical manufacturing and vaccine development, contribute to the region's growth.

Moreover, the emergence of Asia Pacific as a manufacturing hub for pharmaceuticals and biotechnology further drives market expansion in the region. Moreover, China’s Vaccine Contract Manufacturing market held the largest market share, and the Indian Vaccine Contract Manufacturing market was the fastest growing market in the Asia-Pacific region.

**Vaccine Contract Manufacturing Key Market Players & Competitive Insights**

leading players in the Vaccine Contract Manufacturing Market, focusing on expanding their manufacturing capacities, enhancing technological capabilities, and forming strategic partnerships. These companies aim to meet the increasing demand for vaccines, especially in response to public health emergencies like the COVID-19 pandemic. Additionally, leading players are investing in research and market developments to develop innovative vaccine candidates and improve production efficiency. Furthermore, they are leveraging their expertise in regulatory compliance to ensure the quality and safety of vaccine manufacturing processes.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Vaccine Contract Manufacturing industry to benefit clients and increase the market sector. In recent years, the Vaccine Contract Manufacturing industry has offered some of the most significant advantages to Downstream. Major players in the Vaccine Contract Manufacturing market, including Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others, are attempting to increase market demand by investing in research and development operations.

Emergent BioSolutions Inc. is a global leader in vaccine contract manufacturing, offering end-to-end solutions for the development, manufacturing, and distribution of vaccines. With state-of-the-art facilities and advanced bioprocessing capabilities, Emergent specializes in producing vaccines for infectious diseases, biodefense, and public health emergencies. The company's comprehensive services include process development, technology transfer, cGMP manufacturing, fill-finish operations, and regulatory support. Emergent collaborates closely with government agencies, pharmaceutical companies, and nonprofit organizations to address global health challenges and advance vaccine development initiatives.

Leveraging its expertise and commitment to quality, Emergent plays a critical role in enhancing global vaccine preparedness and response efforts, ensuring timely access to safe and effective vaccines for populations worldwide.

Wuxi Biologics is a leading global contract development and manufacturing organization (CDMO) specializing in biologics, including vaccine contract manufacturing. With state-of-the-art facilities and extensive expertise in bioprocessing, Wuxi Biologics offers end-to-end solutions for the development, manufacturing, and commercialization of vaccines. The company's services include cell line development, process optimization, cGMP manufacturing, and fill-finish operations tailored to meet the specific needs of vaccine developers. Wuxi Biologics collaborates with pharmaceutical companies, academic institutions, and government agencies to accelerate vaccine development timelines and ensure regulatory compliance.

Through its commitment to innovation, quality, and customer satisfaction, Wuxi Biologics contributes to advancing global vaccine manufacturing capabilities and addressing public health challenges worldwide.

**Key Companies in the Vaccine Contract Manufacturing market include**

**Vaccine Contract Manufacturing Industry Developments**

February 2025: Emergent BioSolutions: Under an agreement with the United States government, Emergent BioSolutions will provide development and production services for the COVID-19 vaccine frontrunners. The partnership aims to utilize Emergent's manufacturing capacity to further support vaccine development and production efforts.

December 2024 : SK Bioscience and Novavax: SK Bioscience has expanded its contract manufacturing and licensing agreements with Novavax for the COVID-19 vaccine NVX-CoV2373 for international sale and marketing. The provision involves using three out of nine drug substance production facilities of SK Bioscience's L-House plant in South Korea's Andong City up to 2025.

February 2025 : Moderna: Moderna did worse than expected in their quarterly earnings by $0.23. Analysts previously believed that this loss would be lower than that figure. The lack of revenue was mainly from costs associated with shutting down a Covid 19 vaccine contract, where they incurred a loss of $238 million. They took in $966 million, a 66% fall but higher than expected.

Astrazeneca: Astrazenica, after moving their headquarters to Cambridge, ceased support of the vaccine hub in Liverpool and instead, focused their resources towards R&D outside the UK. This change in plans caused the company to scrap the construction of the vaccine/manufacturing plant in Speke, which was set to be built for £450 million to combat the global pandemics and flu viruses.

December 2024: Moderna: The government of Australia recently has enabled legislation that will assist in the provision of mRNA respiratory vaccines built by moderna, set to be deployed in the upcoming year for Australians. And expect no approval from the PBAC per the 2 billion dollar agreement with Morrison's government.

## **Vaccine Contract Manufacturing Market Segmentation**

### **Vaccine Contract Manufacturing Vaccine Type Outlook**

### **Vaccine Contract Manufacturing Workflow Outlook**

### **Vaccine Contract Manufacturing Application Outlook**

### **Vaccine Contract Manufacturing Regional Outlook**

## Market Drivers

### Rising Demand for Vaccines

The Vaccine Contract Manufacturing Market is experiencing a notable increase in demand for vaccines, driven by the growing awareness of preventive healthcare. As populations become more health-conscious, the need for vaccines to combat infectious diseases is escalating. According to recent data, the vaccine market is projected to reach approximately USD 60 billion by 2025, indicating a robust growth trajectory. This surge in demand compels manufacturers to seek contract manufacturing services to scale production efficiently. The Vaccine Contract Manufacturing Market thus benefits from this trend, as companies look to outsource production to meet the rising needs of healthcare providers and governments. Furthermore, the increasing prevalence of vaccine-preventable diseases underscores the necessity for reliable manufacturing partners, enhancing the attractiveness of the contract manufacturing model.

### Regulatory Support and Compliance

Regulatory frameworks are evolving to support the Vaccine Contract Manufacturing Market, facilitating smoother pathways for vaccine production and distribution. Governments are recognizing the importance of vaccines in public health and are streamlining regulatory processes to expedite approvals. This supportive environment encourages manufacturers to engage in contract manufacturing, as compliance with regulations becomes more manageable. The Vaccine Contract Manufacturing Market is likely to see increased participation from new entrants, as the barriers to entry are lowered. Moreover, regulatory agencies are providing guidance on best practices, which enhances the overall quality and safety of vaccine production. As a result, the alignment of regulatory support with industry needs is expected to drive growth in the Vaccine Contract Manufacturing Market, fostering innovation and collaboration among stakeholders.

### Increasing Focus on Vaccine Development

The Vaccine Contract Manufacturing Market is being propelled by an increasing focus on vaccine development, particularly in response to emerging infectious diseases. Governments and private entities are investing heavily in research and development to create new vaccines, which necessitates robust manufacturing capabilities. The market for vaccine development is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 10% in the coming years. This trend creates opportunities for contract manufacturers to collaborate with biotech firms and pharmaceutical companies, providing the necessary infrastructure and expertise to bring new vaccines to market efficiently. As the urgency for innovative vaccine solutions rises, the Vaccine Contract Manufacturing Market stands to benefit from these collaborative efforts, enhancing its role in the broader healthcare ecosystem.

### Cost Efficiency and Resource Optimization

In the Vaccine Contract Manufacturing Market, cost efficiency plays a pivotal role in driving growth. Many pharmaceutical companies are opting for contract manufacturing to reduce operational costs associated with in-house production. By outsourcing vaccine production, companies can allocate resources more effectively, focusing on research and development while leveraging the expertise of specialized manufacturers. This approach not only minimizes capital expenditure but also enhances flexibility in production capacity. Data suggests that companies utilizing contract manufacturing can save up to 30% in production costs, making it an appealing option. As the industry evolves, the emphasis on cost-effective solutions is likely to propel the Vaccine Contract Manufacturing Market further, as firms seek to maintain competitive pricing while ensuring high-quality vaccine production.

### Technological Innovations in Manufacturing

Technological advancements are significantly influencing the Vaccine Contract Manufacturing Market. The integration of cutting-edge technologies such as automation, artificial intelligence, and advanced bioprocessing techniques is enhancing production efficiency and quality. These innovations enable manufacturers to streamline operations, reduce lead times, and improve yield rates. For instance, the adoption of continuous manufacturing processes is transforming traditional batch production methods, allowing for more agile responses to market demands. As a result, the Vaccine Contract Manufacturing Market is likely to witness increased investment in technology-driven solutions, fostering a more competitive landscape. Furthermore, the ability to produce vaccines at a larger scale with consistent quality is becoming a critical factor for success, making technological innovation a key driver in this sector.

## Future Outlook

The Vaccine Contract Manufacturing Market is projected to grow at an 11.5% CAGR from 2025 to 2035, driven by increasing vaccine demand, technological advancements, and strategic partnerships.

**New opportunities:**

- Expansion into emerging markets with tailored vaccine solutions. Investment in advanced bioprocessing technologies for efficiency. Development of flexible manufacturing facilities to accommodate diverse vaccine types.

By 2035, the market is expected to be robust, driven by innovation and strategic growth initiatives.

## Segment Insights

### By Vaccine Type: Inactivated (Largest) vs. Attenuated (Fastest-Growing)

The Vaccine Contract Manufacturing Market exhibits a diverse portfolio of vaccine types, with the inactivated vaccine segment commanding the largest market share due to its widespread use in various immunization programs across the globe. This segment benefits from an established production methodology and greater acceptance from healthcare providers and patients alike, resulting in significant demand. The attenuated vaccines, known for their ability to generate a strong immune response with less antigen, are rapidly gaining traction and are deemed the fastest-growing segment, driven by advancements in technology and rising investments in vaccine R&D.

Inactivated (Dominant) vs. Attenuated (Emerging)

Inactivated vaccines are recognized as the dominant force in the vaccine manufacturing landscape, primarily due to their robustness and safety profile. These vaccines are produced by killing the virus or bacteria, ensuring that they cannot cause disease, which instills confidence among healthcare providers. Conversely, attenuated vaccines, which contain live microbes that have been weakened, are emerging rapidly in the market. Their ability to prompt a strong and lasting immune response makes them especially appealing for new vaccine development, particularly for diseases requiring robust immunity. As innovation continues and regulatory pathways become more streamlined, the presence of attenuated vaccines is anticipated to escalate, positioning them as a key player in future vaccine strategies.

### By Workflow: Downstream (Largest) vs. Upstream (Fastest-Growing)

In the Vaccine Contract Manufacturing Market, the distribution of market share between downstream and upstream workflows illustrates a clear dominance of downstream processes. This segment encompasses crucial stages such as formulation, filling, and packaging, which contribute significantly to the overall manufacturing process. Downstream workflows hold a larger share due to their essential role in ensuring vaccines are effectively prepared for distribution and administration, catering to increasing demand from healthcare providers and governments.

Workflow: Downstream (Dominant) vs. Upstream (Emerging)

The downstream workflow in vaccine contract manufacturing plays a pivotal role due to its focus on the final stages of vaccine production, including formulation, filling, and packaging. This segment is foundational for ensuring product quality and compliance with stringent regulations. As a dominant force in the market, it benefits from established processes and large-scale operations, driving efficiency. In contrast, the upstream segment, which includes processes like cell culture and fermentation, is witnessing rapid growth driven by advancements in bioprocessing technologies and an increase in vaccine research and development efforts, positioning it as an emerging priority for manufacturers.

### By Application: Human Use (Largest) vs. Veterinary (Fastest-Growing)

The Vaccine Contract Manufacturing Market is predominantly driven by the Human Use segment, which holds a significant share due to the increasing demand for vaccines triggered by ongoing health issues and an aging population. This segment continues to dominate, fueled by extensive investments from various stakeholders aimed at enhancing vaccine production capacity and innovation. Conversely, the Veterinary segment, although smaller, is catching up rapidly due to the rise in pet ownership and the growing awareness of [animal health](https://www.marketresearchfuture.com/reports/animal-health-market-7163), which has spurred demand for animal vaccines.

Human Use (Dominant) vs. Veterinary (Emerging)

The Human Use segment is well-established and continues to be the dominant force in the Vaccine Contract Manufacturing Market. Its strength lies in its robust infrastructure, extensive research and development, and a vast network of distributors and healthcare providers. In contrast, the Veterinary segment is emerging as a key player, propelled by increasing investments in animal health and advancements in vaccine technology. This segment is characterized by rapid innovation and a growing consumer base concerned with animal welfare, positioning it strongly for future growth.

## Regional Market Share Analysis

### North America : Leading Innovation and Demand

North America is the largest market for vaccine contract manufacturing, holding approximately 45% of the global share. The region benefits from advanced technological infrastructure, significant investments in R&D, and a robust regulatory framework that encourages innovation. The increasing demand for vaccines, especially post-pandemic, is driving growth, with a focus on rapid production capabilities and quality assurance. The United States is the dominant player, home to key manufacturers like Catalent and KBI Biopharma. Canada also plays a significant role, contributing to the market with its growing biopharmaceutical sector. The competitive landscape is characterized by collaborations between biotech firms and contract manufacturers, enhancing production efficiency and expanding service offerings.

### Europe : Regulatory Framework and Growth

Europe is the second-largest market for vaccine contract manufacturing, accounting for around 30% of the global market share. The region's growth is driven by stringent regulatory standards, which ensure high-quality production processes. The European Medicines Agency (EMA) plays a crucial role in facilitating vaccine approvals, thus boosting market confidence and demand. The increasing focus on pandemic preparedness is also a significant catalyst for growth. Germany and Switzerland are leading countries in this sector, hosting major players like Boehringer Ingelheim and Lonza. The competitive landscape is marked by a mix of established firms and emerging biotech companies, fostering innovation and collaboration. The presence of advanced manufacturing facilities and a skilled workforce further enhances Europe's position in The Vaccine Contract Manufacturing Market.

### Asia-Pacific : Rapid Growth and Investment

Asia-Pacific is witnessing rapid growth in the vaccine contract manufacturing market, holding approximately 20% of the global share. The region's expansion is fueled by increasing investments in biotechnology and a growing demand for vaccines, particularly in countries like China and India. Government initiatives aimed at enhancing healthcare infrastructure and vaccine production capabilities are significant growth drivers, alongside a rising population and awareness of vaccination benefits. China is a key player, with companies like WuXi AppTec leading the market. India is also emerging as a significant contributor, supported by its vast pharmaceutical industry. The competitive landscape is characterized by a mix of local and international players, with collaborations enhancing production capabilities and technological advancements in the region.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region is gradually emerging in the vaccine contract manufacturing market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments and a rising demand for vaccines, particularly in response to public health challenges. Governments are focusing on improving healthcare infrastructure and regulatory frameworks to attract foreign investments, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are leading the way, with initiatives aimed at boosting local manufacturing capabilities. The competitive landscape is still developing, with opportunities for both local and international players to establish a presence. The region's resource-rich environment and strategic location offer significant potential for future growth in vaccine manufacturing.

## Competitive Benchmarking

The Vaccine Contract Manufacturing Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for vaccine production capabilities and the necessity for rapid response to emerging health threats. Key players such as Lonza (CH), Boehringer Ingelheim (DE), and Samsung Biologics (KR) are strategically positioned to leverage their extensive manufacturing networks and technological expertise. Lonza (CH) focuses on innovation in biopharmaceutical manufacturing, while Boehringer Ingelheim (DE) emphasizes partnerships to enhance its production capabilities. Samsung Biologics (KR) is expanding its facilities to meet global demand, indicating a trend towards regional expansion and capacity enhancement among leading firms. Collectively, these strategies contribute to a competitive environment that prioritizes agility and responsiveness to market needs. In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and optimize logistics. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure fosters an environment where innovation and operational efficiency are paramount, as firms seek to differentiate themselves in a crowded marketplace.
In August Lonza (CH) announced a significant investment in its biologics manufacturing facility in Switzerland, aimed at increasing its production capacity for viral vector-based vaccines. This strategic move is likely to enhance Lonza's ability to meet the growing demand for advanced therapies, positioning the company as a leader in the production of complex biologics. The investment underscores the importance of scaling operations to maintain competitive advantage in a rapidly evolving market.
In September Boehringer Ingelheim (DE) entered into a collaboration with a leading biotech firm to co-develop a new vaccine platform. This partnership is indicative of a broader trend towards collaborative innovation, allowing Boehringer Ingelheim to leverage external expertise while expanding its own capabilities. Such strategic alliances are essential for accelerating the development of novel vaccines and enhancing the company’s market position.
In July Samsung Biologics (KR) unveiled plans to construct a new state-of-the-art manufacturing facility in South Korea, which is expected to be operational by late 2026. This expansion reflects Samsung's commitment to increasing its production capacity and technological capabilities, thereby solidifying its role as a key player in the global vaccine manufacturing landscape. The facility is anticipated to incorporate advanced automation and digital technologies, aligning with current trends in manufacturing efficiency.
As of October the competitive trends in the Vaccine Contract Manufacturing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise for enhanced innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancement, supply chain reliability, and the ability to respond swiftly to emerging health challenges.

## Recent News & Developments

February 2025: Emergent BioSolutions: Under an agreement with the United States government, Emergent BioSolutions will provide development and production services for the COVID-19 vaccine frontrunners. The partnership aims to utilize Emergent's manufacturing capacity to further support vaccine development and production efforts.

December 2024 : SK Bioscience and Novavax: SK Bioscience has expanded its contract manufacturing and licensing agreements with Novavax for the COVID-19 vaccine NVX-CoV2373 for international sale and marketing. The provision involves using three out of nine drug substance production facilities of SK Bioscience's L-House plant in South Korea's Andong City up to 2025.

February 2025 : Moderna: Moderna did worse than expected in their quarterly earnings by $0.23. Analysts previously believed that this loss would be lower than that figure. The lack of revenue was mainly from costs associated with shutting down a Covid 19 vaccine contract, where they incurred a loss of $238 million. They took in $966 million, a 66% fall but higher than expected.

Astrazeneca: Astrazenica, after moving their headquarters to Cambridge, ceased support of the vaccine hub in Liverpool and instead, focused their resources towards R&D outside the UK. This change in plans caused the company to scrap the construction of the vaccine/manufacturing plant in Speke, which was set to be built for £450 million to combat the global pandemics and flu viruses.

December 2024: Moderna: The government of Australia recently has enabled legislation that will assist in the provision of mRNA respiratory vaccines built by moderna, set to be deployed in the upcoming year for Australians. And expect no approval from the PBAC per the 2 billion dollar agreement with Morrison's government.

## Report Scope

| MARKET SIZE 2024 | 3.7(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 4.126(USD Billion) |
| MARKET SIZE 2035 | 12.25(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lonza (CH), Boehringer Ingelheim (DE), Samsung Biologics (KR), Catalent (US), WuXi AppTec (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Fujifilm Diosynth Biotechnologies (JP), Vetter Pharma (DE) |
| Segments Covered | Vaccine Type, Workflow, Application, Region |
| Key Market Opportunities | Emerging biomanufacturing technologies enhance efficiency in the Vaccine Contract Manufacturing Market. |
| Key Market Dynamics | Rising demand for innovative vaccine technologies drives competition and regulatory adaptations in the contract manufacturing landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Vaccine Contract Manufacturing Market?**
A: The market valuation was 3.7 USD Billion in 2024.

**Q: What is the projected market size for the Vaccine Contract Manufacturing Market by 2035?**
A: The market is projected to reach 12.25 USD Billion by 2035.

**Q: What is the expected CAGR for the Vaccine Contract Manufacturing Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market is 11.5% during the forecast period.

**Q: Which companies are considered key players in the Vaccine Contract Manufacturing Market?**
A: Key players include Lonza, Boehringer Ingelheim, Samsung Biologics, Catalent, and WuXi AppTec.

**Q: What are the different types of vaccines included in the market segments?**
A: The market segments include Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based vaccines.

**Q: What was the valuation of the Inactivated vaccine segment in 2024?**
A: The Inactivated vaccine segment was valued at 1.2 USD Billion in 2024.

**Q: What is the projected valuation for the Human Use application segment by 2035?**
A: The Human Use application segment is projected to reach 8.0 USD Billion by 2035.

**Q: How does the Downstream workflow segment compare to the Upstream workflow segment in terms of valuation?**
A: The Downstream workflow segment was valued at 1.85 USD Billion in 2024, while the Upstream segment was also valued at 1.85 USD Billion.

**Q: What is the projected growth for the Veterinary application segment by 2035?**
A: The Veterinary application segment is projected to grow to 4.25 USD Billion by 2035.

**Q: What does the market data suggest about the future of the Vaccine Contract Manufacturing Market?**
A: The data suggests a robust growth trajectory, with a projected increase in market valuation and a strong CAGR of 11.5% from 2025 to 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/vaccine-contract-manufacturing-market-22012*